文献速递认知障碍与痴呆

很可能阿尔茨海默病的认知异质性:临床与神经病理特征

Cognitive heterogeneity in probable Alzheimer disease: Clinical and neuropathologic features.
PubMed 文献 · Neurology · 2019-07-18

研究基于国家阿尔茨海默病协调中心4711例轻中度很可能AD患者,应用临床试验入排标准,在800例尸检证实AD中通过主成分分析和基于模型的聚类识别认知亚型,并在整体样本及独立队列中验证。尸检样本中79.6%为典型AD认知特征(情景记忆损害更重),20.4%为非典型(各认知域损害相当);非典型与较年轻、男性、APOE ε4概率较低、整体痴呆较轻、抑郁评分较高、尸检Braak分期较低及认知下降较慢相关。

要点

  • 很可能AD患者中约20%表现为非典型认知特征,各认知域损害程度相当。
  • 非典型认知特征与较低Braak分期和较慢认知下降相关。
  • 认知亚型识别对AD临床试验(尤其靶向tau治疗)可能有意义。

核心结论

  • 临床诊断的很可能是AD患者中可可靠识别出不同认知特征,这些特征与缠结病理和认知下降速率相关。

研究设计与样本

  • 研究从国家阿尔茨海默病协调中心获取4711例轻中度很可能AD患者的神经心理测试数据,并应用AD临床试验常用入排标准。
  • 在800例尸检证实的AD亚组中使用主成分分析和基于模型的聚类识别认知特征,并在整体非尸检样本及具有相似测试数据的独立队列中验证。
  • 采用混合效应模型分析认知特征与临床特征及下降速率的关系。

主要发现

  • 尸检确认样本中79.6%患者为典型AD认知特征(情景记忆损害比其他认知功能更重),20.4%为非典型特征(各认知域损害相当)。
  • 整体样本中典型占79.8%、非典型占20.2%;验证样本中典型占71.8%、非典型占28.2%。
  • 非典型特征与较年轻年龄、男性、APOE ε4概率较低、整体痴呆较轻、抑郁评分较高、尸检Braak分期较低及认知下降较慢相关。

临床怎么用

  • 在临床和试验中应关注很可能AD患者的认知异质性,非典型特征者可能疾病进展较慢。
  • 针对tau的AD临床试验设计可考虑认知亚型分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To identify heterogeneity in cognitive profiles of patients with probable Alzheimer disease (AD) who have mild to moderate dementia and satisfy inclusion and exclusion criteria for a typical AD clinical trial, and to determine whether cognitive profiles are systematically related to the clinical course and neuropathologic features of the disease. METHODS: Neuropsychological test data from patients with mild to moderate probable AD (n = 4,711) were obtained from the National Alzheimer's Coordinating Center. Inclusion and exclusion criteria usually used in AD clinical trials were applied. Principal component analysis and model-based clustering were used to identify cognitive profiles in a subset of patients with autopsy-verified AD (n = 800) and validated in the overall (nonautopsy) sample and an independent cohort with similar test data. Relationships between cognitive profile, clinical characteristics, and rate of decline were examined with mixed-effects models. RESULTS: In the autopsy-confirmed sample, 79.6% of patients had a typical AD cognitive profile (greater impairment of episodic memory than other cognitive functions), and 20.4% had an atypical profile (comparable impairment across cognitive domains). Similar results were obtained in the overall (typical 79.8%, atypical 20.2%) and validation (typical 71.8%, atypical 28.2%) samples. Atypicality was associated with younger age, male sex, lower probability of APOE ε4, less severe global dementia, higher depression scores, lower Braak stage at autopsy, and slower cognitive decline. CONCLUSION: We can reliably identify distinct cognitive profiles among patients with clinically diagnosed probable AD that are associated with tangle pathology and with different rates of decline. This may have implications for clinical trials in AD, especially therapies targeting tau.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Qiu Y, Jacobs DM, Messer K, et al. Cognitive heterogeneity in probable Alzheimer disease: Clinical and neuropathologic features. Neurology. 2019. PMID: 31320469. doi:10.1212/WNL.0000000000007967

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。